Furthermore, a risk prediction model was built based on TCGA data, and the results indicated that high-risk patients with low expression of RRAD and high expression of GLUT3 simultaneously had a poorer prognosis and a higher rate of lymph node metastases (Fig. 6F). Here, RRAD is linked to metastatic malignant neoplasm in the lymph nodes.